Middle East respiratory syndrome: obstacles and prospects for vaccine development

Area of Science:

• Vaccinology
• Emerging Infectious Diseases
• Biotechnology

Background:

• The emergence of Middle East respiratory syndrome (MERS) necessitates accelerated vaccine development strategies.
• Current vaccine development timelines are lengthy, posing challenges for emerging diseases.
• Obstacles include the lack of suitable animal models and limited commercial incentive for MERS vaccine production.

Purpose of the Study:

• To explore novel methods for expediting vaccine development against MERS.
• To address the challenges hindering the production of a licensable MERS vaccine.
• To propose cost-effective and rapid vaccine engineering strategies.

Main Methods:

• Investigating genetically engineered vaccine platforms.
• Exploring novel methods and cost-saving strategies for vaccine production.
• Considering advancements in MERS animal model development.

Main Results:

• Genetically engineered vaccines can be produced quickly and cost-effectively.
• Novel methods can mitigate or circumvent obstacles in MERS vaccine development.
• Progress in animal models is crucial for in vivo testing.

Conclusions:

• Genetically engineered vaccines present a viable solution for rapid MERS vaccine development.
• Addressing animal model limitations and economic factors is key to overcoming MERS vaccine production hurdles.
• Accelerated vaccine development is achievable through innovative approaches and strategic mitigation of challenges.